Incyte Corporation
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-42.5% vs price
Base Case (Median)
-27.0% vs price
Bull Case (75th pct.)
50.4% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $73.73 | -40.3% | High (40%) |
| PE Comparable | $174.70 | 41.5% | Medium (25%) |
| Growth Trajectory DCF | $395.41 | 220.2% | Medium (20%) |
| Graham Number | $68.38 | -44.6% | Medium (40%) |
| EV/EBITDA | $90.17 | -27.0% | Medium (20%) |
| EV/FCF | $196.77 | 59.3% | Medium (20%) |
| Earnings Power Value | $56.75 | -54.0% | Medium (50%) |
Based on 7 out of 8 methods, INCY appears fairly valued at the current price of $123.50. The base case fair value of $90.17 implies 27.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.